Key clinical point: A novel oral small molecule’s potent anti-inflammatory effect over 8 weeks was associated with significant endoscopic improvement, reduced Mayo scores, and a trend toward clinical response, compared with placebo.
Major finding: At 8 weeks, 43% of patients receiving ABX464 had an endoscopic Mayo score of 0 or 1, compared with 11% taking placebo (P = .03).Study details: Randomized, double-blind, placebo-controlled study of 32 patients with moderate to severe ulcerative colitis.
Disclosures: The study was sponsored by Abivax. Dr. Steens is an employee of and holds shares of Abivax.
Vermeire S et al. DDW, Abstract 1007.